Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy.

Autor: Li F; Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, 410013, China., Liu J; Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, 410013, China., Fu Y; Department of Blood Transfusion, The Third Xiangya Hospital of Central South University, Changsha, 410013, China. fuyunfeng@csu.edu.cn.
Jazyk: angličtina
Zdroj: Current treatment options in oncology [Curr Treat Options Oncol] 2024 Nov; Vol. 25 (11), pp. 1354-1365. Date of Electronic Publication: 2024 Oct 21.
DOI: 10.1007/s11864-024-01273-6
Abstrakt: Opinion Statement: Multiple myeloma (MM) is a heterogeneous plasma cell tumor with a survival period of several months to over ten years. Despite the development of various new drugs, MM is still incurable and recurs repeatedly. Bortezomib, a landmark event in the history of MM treatment, has dramatically improved the prognosis of patients with MM. Although proteasome inhibitors (PIs) represented by bortezomib, have greatly prolonged MM survival, unfortunately, almost all MM will develop bortezomib resistance, leading to relapse with a shorter survival. It has been reported that both the tumor microenvironment and myeloma cells drive bortezomib resistance. Multiple treatment methods have been attempted to overcome bortezomib resistance, but unfortunately, there has been no breakthrough. It is believed that the key resistance mechanism has not yet been discovered. A deeper understanding of the mechanism of bortezomib resistance and strategies to overcome it can help identify key resistance mechanisms and further improve the prognosis of MM.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: